What question did this study set out to answer?

To compare the long-term clinical efficacy and microvascular effects of short-term intravenous iloprost infusions with oral nifedipine in systemic sclerosis-associated Raynaud's phenomenon.

March 4, 1989BMJOpen Access

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

View Full Paper

Ask AI

Bookmark

Authors

MRMarius RademakerWaikato Hospital ECE D CookeUniversity College Cork NAN. E. AlmondUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates sustained symptom relief and improved blood flow with iloprost in systemic sclerosis, suggesting clinical advantages over oral nifedipine.

Key Points

To compare the long-term clinical efficacy and microvascular effects of short-term intravenous iloprost infusions with oral nifedipine in systemic sclerosis-associated Raynaud's phenomenon.
Double-blind, placebo-controlled randomized trial involving 23 outpatient dermatology clinic patients with systemic sclerosis and capillaroscopy-confirmed Raynaud's phenomenon.
Patients received either intravenous iloprost (0.5 to 2.0 ng/kg/min for 8 hours on 3 consecutive days, repeated at week 8) with placebo capsules (n=12), or oral nifedipine (30 mg escalated to 60 mg daily) with placebo infusions (n=11).
Evaluated attack frequency, duration, severity, digital ulcer lesions, and digital blood flow over 16 weeks of follow-up.
Both treatments reduced the frequency, duration, and severity of Raynaud's attacks; digital lesions decreased from a mean (SE) of 3.5 (1.6) to 0.6 (0.3) with iloprost and 4.3 (0.8) to 1.4 (0.5) with nifedipine at week 16.
Hand temperature and digital microcirculatory blood flow increased significantly following iloprost infusions, whereas nifedipine produced no detectable improvement in blood flow.
Adverse effects led three patients in the nifedipine group to discontinue treatment, while iloprost-related side effects were strictly dose-dependent, occurring only during active infusions.

Cite This Study

Rademaker et al. (1989) studied this question.

synapsesocial.com/papers/6a6fdf3b8031ec7bb1dbfb6e https://doi.org/10.1136/bmj.298.6673.561

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates sustained symptom relief and improved blood flow with iloprost in systemic sclerosis, suggesting clinical advantages over oral nifedipine.

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider